D), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in theJournal of the European Academy of Dermatology and Venereology.

Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response.

Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as
=*=*=*=*=*=
当前为第2/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页